NFA
BNGO icon

Northwest Financial Advisors’s Bionano Genomics BNGO Stock Holding History

Northwest Financial Advisors’s Portfolio BNGO Stock Details BNGO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-3
Closed -$378 – 141
2023
Q4 		$378 Buy
+3
New +$313 ﹤0.01% 536

Other funds holding BNGO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Cetera Investment Advisers
Cetera Investment Advisers Schaumburg, Illinois $94B AUM 20.14% 1-Year Est. Return
CA
Cetera Advisors Denver, Colorado $12.7B AUM 22.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Northwest Financial Advisors's BNGO Position: Q1 2024 in Review

Northwest Financial Advisors sold out of Bionano Genomics (BNGO) in Q1 2024, closing a stake of 3 shares — an estimated $378 sold.

Northwest Financial Advisors first reported a position in BNGO in Q4 2023 and held it in 1 quarter. The position peaked at $378 in Q4 2023. 55 funds tracked by Wall St. Rank hold BNGO as of Q1 2024.

  • Northwest Financial Advisors reported no remaining Bionano Genomics position as of Q1 2024 after selling out during the quarter.
  • Northwest Financial Advisors sold 3 Bionano Genomics shares in Q1 2024, an estimated $378.
  • Northwest Financial Advisors first reported a position in Bionano Genomics in Q4 2023 and held it in 1 quarter.
  • Northwest Financial Advisors's Bionano Genomics position peaked at $378 in Q4 2023.
  • 55 funds tracked by Wall St. Rank held Bionano Genomics as of Q1 2024.

Based on Northwest Financial Advisors's 13F filing for Q1 2024, filed 9 May 2024.